EMA Refused: Eladynos (abaloparatide) — Radius Health Ireland Ltd

View source ↗

Summary

The EMA refused the marketing authorization for Eladynos (abaloparatide) for osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Eladynos (abaloparatide)

Snippet

Status: Refused. Therapeutic area: Osteoporosis. MAH: Radius Health Ireland Ltd. Decision date: 03/04/2018